Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CUTR NASDAQ:NDRA NASDAQ:NVNO NASDAQ:NXL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCUTRCutera$0.10$0.04$0.09▼$1.63$1.96M1.362.97 million shsN/ANDRAENDRA Life Sciences$5.60+2.6%$4.78$2.91▼$11.96$7.11M-0.1114,780 shs8,039 shsNVNOenVVeno Medical$10.68-2.6%$10.91$8.67▼$196.70$7.16M1.0814,280 shs11,505 shsNXLNexalin Technology$0.38$0.39$0.31▼$2.00$7.77M3.56246,174 shs16.47 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCUTRCutera0.00%0.00%0.00%0.00%+148.46%NDRAENDRA Life Sciences0.00%+10.89%+12.68%+49.33%+80.06%NVNOenVVeno Medical0.00%+8.87%-18.16%-5.40%-90.89%NXLNexalin Technology0.00%+10.28%-11.32%-22.92%-69.29%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCUTRCutera$0.10$0.04$0.09▼$1.63$1.96M1.362.97 million shsN/ANDRAENDRA Life Sciences$5.60+2.6%$4.78$2.91▼$11.96$7.11M-0.1114,780 shs8,039 shsNVNOenVVeno Medical$10.68-2.6%$10.91$8.67▼$196.70$7.16M1.0814,280 shs11,505 shsNXLNexalin Technology$0.38$0.39$0.31▼$2.00$7.77M3.56246,174 shs16.47 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCUTRCutera0.00%0.00%0.00%0.00%+148.46%NDRAENDRA Life Sciences0.00%+10.89%+12.68%+49.33%+80.06%NVNOenVVeno Medical0.00%+8.87%-18.16%-5.40%-90.89%NXLNexalin Technology0.00%+10.28%-11.32%-22.92%-69.29%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCUTRCutera 0.00N/AN/AN/ANDRAENDRA Life Sciences 2.00Hold$30.00435.71% UpsideNVNOenVVeno Medical 1.50ReduceN/AN/ANXLNexalin Technology 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest CUTR, NDRA, NXL, and NVNO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/20/2026NDRAENDRA Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026NVNOenVVeno Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 5/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCUTRCutera$155.21M0.01N/AN/A($8.62) per share-0.01NDRAENDRA Life SciencesN/AN/AN/AN/A$1.41 per shareN/ANVNOenVVeno MedicalN/AN/AN/AN/A$35.57 per shareN/ANXLNexalin Technology$275.58K28.21N/AN/A$0.14 per share2.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCUTRCutera-$162.83M-$6.58N/AN/AN/A-84.86%N/A-45.07%N/ANDRAENDRA Life Sciences-$7.03M-$8.15N/AN/AN/AN/A-433.64%-204.58%8/13/2026 (Estimated)NVNOenVVeno Medical-$19.47M-$25.54N/AN/AN/AN/A-66.39%-60.42%7/30/2026 (Estimated)NXLNexalin Technology-$8.22M-$0.47N/AN/AN/A-3,018.12%-191.88%-166.43%6/3/2026 (Estimated)Latest CUTR, NDRA, NXL, and NVNO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/3/2026N/ANXLNexalin Technology-$0.10N/AN/AN/A$0.02 millionN/A5/18/2026Q1 2026NDRAENDRA Life Sciences-$1.23-$1.09+$0.14-$1.09N/AN/A5/8/2026Q1 2026NXLNexalin Technology-$0.10-$0.11-$0.01-$0.11$0.02 million$0.01 million5/7/2026Q1 2026NVNOenVVeno Medical-$8.40-$5.89+$2.51-$5.89$0.50 millionN/A3/25/2026Q4 2025NXLNexalin Technology-$0.12-$0.13-$0.01-$0.13$0.08 million$0.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCUTRCuteraN/AN/AN/AN/AN/ANDRAENDRA Life SciencesN/AN/AN/AN/AN/ANVNOenVVeno MedicalN/AN/AN/AN/AN/ANXLNexalin TechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCUTRCuteraN/A2.881.86NDRAENDRA Life SciencesN/A0.641.29NVNOenVVeno MedicalN/A11.8911.89NXLNexalin TechnologyN/A4.073.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCUTRCutera90.70%NDRAENDRA Life Sciences1.19%NVNOenVVeno Medical34.71%NXLNexalin Technology0.65%Insider OwnershipCompanyInsider OwnershipCUTRCutera0.42%NDRAENDRA Life Sciences10.00%NVNOenVVeno Medical15.00%NXLNexalin Technology25.26%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCUTRCutera46020.19 million20.10 millionNo DataNDRAENDRA Life Sciences201.27 million1.14 millionNot OptionableNVNOenVVeno Medical30670,000568,000OptionableNXLNexalin Technology320.58 million15.38 millionNot OptionableCUTR, NDRA, NXL, and NVNO HeadlinesRecent News About These CompaniesNexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research ...May 21, 2026 | markets.businessinsider.comNexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain InjuryMay 21, 2026 | globenewswire.comNexalin Technology, Inc.: Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO Clarity and Nexalin NeuroCare Ahead of Planned FDA Pivotal TrialMay 20, 2026 | finanznachrichten.deNexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal TrialMay 19, 2026 | globenewswire.comNexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic ...April 28, 2026 | finance.yahoo.comNexalin Technology (NXL) price target decreased by 50.00% to 2.04April 28, 2026 | msn.comNexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic InsomniaApril 28, 2026 | globenewswire.comMaxim Group Remains a Buy on Nexalin Technology, Inc. (NXL)April 23, 2026 | theglobeandmail.comNexalin Advances Pivotal Insomnia Trial for HALO ClarityApril 22, 2026 | tipranks.comNexalin Technology, Inc. to Advance Pivotal Clinical Trial for HALO™ Clarity Device Aimed at Treating Moderate-to-Severe InsomniaApril 22, 2026 | quiverquant.comQNexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 EnrollmentApril 22, 2026 | globenewswire.comNexalin Advances FDA Alzheimer’s Strategy Following Landmark Leadership Meetings in the U.S. and ChinaApril 16, 2026 | finance.yahoo.comNexalin Technology, Inc.: Nexalin Advances FDA Alzheimer's Strategy Following Landmark Leadership Meetings in the U.S. and ChinaApril 16, 2026 | finanznachrichten.deNexalin Advances FDA Alzheimer's Strategy Following Landmark Leadership Meetings in the U.S. and ChinaApril 15, 2026 | globenewswire.comJoin Nexalin’s Exclusive Live Investor Webinar and Q&A Session on April 21April 15, 2026 | finance.yahoo.comJoin Nexalin's Exclusive Live Investor Webinar and Q&A Session on April 21April 14, 2026 | globenewswire.comNexalin Announces Peer-Reviewed Study Showing the Company’s DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female AdolescentsApril 10, 2026 | markets.businessinsider.comNexalin Technology, Inc. Reports Significant Reductions in Self-Injury Behaviors and Depressive Symptoms in BMC Psychiatry Publication on DIFS ApproachApril 9, 2026 | quiverquant.comQNexalin Announces Peer-Reviewed Study Showing the Company's DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female AdolescentsApril 9, 2026 | globenewswire.comNexalin Technology, Inc.: Nexalin Announces Pivotal HALO Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia MarketFebruary 25, 2026 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCUTR, NDRA, NXL, and NVNO Company DescriptionsCutera NASDAQ:CUTRCutera, Inc. provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designs to strengthen, firm and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform. It also offers truSculpt, a high-powered radio frequency system designed for circumferential reduction, lipolysis, and deep tissue heating and treat all skin types; Secret RF, a fractional RF microneedling device that delivers heat into the deeper layers of the skin using controlled RF energy; and Enlighten SR/III, a laser platform with a dual wavelength for multi-colored tattoo removal, and the treatment of benign pigmented lesions and acne scars. In addition, the company provides Excel HR, a hair removal solution for all skin types; xeo, a multi-application platform for the removal of unwanted hair, treatment of vascular lesions, and skin revitalization by treating discoloration, fine lines, and laxity; and Secret DUO, two dual non-ablative fractional technologies that can be used individually or in combination to target a variety of aesthetic concerns and skin conditions on all skin types with little to no downtime. Further, it offers its products through direct sales and services, and network of distributors and direct international sales. Cutera, Inc. was incorporated in 1998 and is headquartered in Brisbane, California.ENDRA Life Sciences NASDAQ:NDRA$5.60 +0.14 (+2.56%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$5.52 -0.08 (-1.43%) As of 05/22/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.enVVeno Medical NASDAQ:NVNO$10.68 -0.28 (-2.55%) Closing price 05/22/2026 03:50 PM EasternExtended Trading$9.60 -1.08 (-10.10%) As of 05/22/2026 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial. Nexalin Technology NASDAQ:NXL$0.38 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$0.40 +0.02 (+5.11%) As of 05/22/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Ross Stores Earnings Beat Sends Stock To New Highs Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins Apparel Earnings Winners and Losers: Ralph Lauren Takes Off SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? The Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May Appear Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
